ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG)

ACMG Secondary Findings Working Group

Research output: Contribution to journalEditorialpeer-review

161 Scopus citations
Original languageEnglish (US)
Pages (from-to)1407-1414
Number of pages8
JournalGenetics in Medicine
Volume24
Issue number7
DOIs
StatePublished - Jul 2022

Funding

Funding and support listed here did not support development of this document unless included in the Acknowledgments section. N.S.A.-H. was previously employed by the Regeneron Genetics Center, has received an honorarium from Genentech, and is a member of the scientific advisory board of Allelica, Inc. W.K.C. is a member of the scientific advisory board of Regeneron Genetics Center. D.T.M. has received honoraria from Ambry Genetics and PreventionGenetics LLC. D.R.S. is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics of the National Cancer Institute, Rockville, MD, United States, and also performs contract clinical telehealth services for Genome Medical, Inc in accordance with relevant National Cancer Institute ethics policies. All other authors declare no conflicts of interest. Funding and support listed here did not support development of this document unless included in the Acknowledgments section. N.S.A.-H. was previously employed by the Regeneron Genetics Center, has received an honorarium from Genentech, and is a member of the scientific advisory board of Allelica, Inc. W.K.C. is a member of the scientific advisory board of Regeneron Genetics Center. D.T.M. has received honoraria from Ambry Genetics and PreventionGenetics LLC. D.R.S. is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics of the National Cancer Institute , Rockville, MD, United States, and also performs contract clinical telehealth services for Genome Medical, Inc in accordance with relevant National Cancer Institute ethics policies. All other authors declare no conflicts of interest.

Keywords

  • Exome sequencing
  • Genome sequencing
  • Incidental findings
  • Secondary findings

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this